From the American Society of Clinical Oncology.
Submitted August 4, 2000; accepted August 7, 2000.
Address reprint requests to American Society of Clinical Oncology, 1900 Duke St, Suite 200, Alexandria, VA 22314; email guidelines@@ asco.org.
Adopted on July 21, 2000, by the American Society of Clinical Oncology.
Manuscript editing was completed by H. Ozer and M. Somerfield.
*The American Society of Clinical Oncology considers adherence to these guidelines to be voluntary. The ultimate determination regarding their application is to be made by the physician in light of each patient’s individual circumstances. In addition, these guidelines describe administration of therapies in clinical practice; they cannot be assumed to apply to interventions performed in the context of clinical trials, given that such clinical studies are designed to test innovative and novel therapies for this symptom in which better treatment is of paramount importance. In that guideline development involves a review and synthesis of the latest literature, a practice guideline also serves to identify important questions for further research and those settings in which investigational therapy should be considered.
